Poehling Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
JFG
Poehling Capital Management's XBI Position: Q2 2026 in Review
Poehling Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.4% in Q2 2026, selling an estimated $12.4K and leaving 2,585 shares worth $409K. The position accounts for 0.09% of the portfolio, ranked #112.
Poehling Capital Management first reported a position in XBI in Q4 2017 and has held it in 22 quarters since. The position peaked at $911K in Q1 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Poehling Capital Management held 2,585 shares of State Street SPDR S&P Biotech ETF worth $409K as of Q2 2026.
- Poehling Capital Management sold 92 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $12.4K.
- State Street SPDR S&P Biotech ETF made up 0.09% of Poehling Capital Management's portfolio in Q2 2026, its #112 holding.
- Poehling Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 22 quarters since.
- Poehling Capital Management's State Street SPDR S&P Biotech ETF position peaked at $911K in Q1 2022.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Poehling Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.